Multiple antitumor mechanisms downstream of prophylactic regulatory T-ceII depletion

Cancer Research

Volumn 70, Issue 7, 2010, Pages 2665-2674

  Teng, Michele W L ^a,b   Swann, Jeremy B ^a,b   Von Scheidt, Bianca ^a   Sharkey, Janelle ^a   Zerafa, Nadeen ^a   McLaughlin, Nicole ^a   Yamaguchi, Tomoyuki ^c   Sakaguchi, Shimon ^c   Darcy, Phillip K ^a,b   Smyth, Mark J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; BASILIXIMAB; FOLATE RECEPTOR ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 4; MONOCLONAL ANTIBODY; OKT 4; PERFORIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; FIBROSARCOMA; KIDNEY CARCINOMA; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR REJECTION;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; FIBROSARCOMA; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; METHYLCHOLANTHRENE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES, REGULATORY;

EID: 77950794689     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1574     Document Type: Article

References (37)

1. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a) monoclonal antibody. Cancer Res 1999;59:3128-3133
2. Golgher D, Jones E, Powrie F, Elliott T, Gallimore A. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 2002;32:3267-3275 (Pubitemid 35414884)
3. Tawara I, Take Y, Uenaka A, Noguchi Y, Nakayama E. Sequential involvement of two distinct CD4+ regulatory T cells during the course of transplantable tumor growth and protection from 3methylcholanthrene-induced tumorigenesis by CD25-depletion. Jpn J Cancer Res 2002;93:911-916 (Pubitemid 35012253)
4. Yu P, Lee Y, Liu W, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005;201:779-791 (Pubitemid 40395122)
5. Casares N, Arribillaga L, Sarobe P, et al. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-ydependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 2003;171: 5931-5939 (Pubitemid 37467211)
6. Ko K, Yamazaki S, Nakamura K, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumorinfiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005; 202:885-891
7. Chen ML, Pittet MJ, Gorelik L, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sci U S A 2005;102:419-424 (Pubitemid 40116782)
8. den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts. Cancer Res 2005;65:6984-6989 (Pubitemid 41065084)
9. Ghiringhelli F, Menard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 2006;214:229-238 (Pubitemid 44707914)
10. Ghiringhelli F, Menard C, Terme M, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J Exp Med 2005;202:1075-1085
11. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK cellmediated immunotherapy of cancer. J Immunol 2006;176:1582-1587
12. Terme M, Chaput N, Combadiere B, Ma A, Ohteki T, Zitvogel L. Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+ self-reactive T cells. J Immunol 2008;180:4679-4686
13. Yamaguchi T, Hirota K, Nagahama K, et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 2007;27:145-159 (Pubitemid 47089022)
14. Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 2008;205:2125-2138
15. Seki N, Brooks AD, Carter CR, et al. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 2002;168:3484-3492
16. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001;13:459-463
17. Smyth MJ, Thia KY, Street SE, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661-668
18. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002;196:119-127 (Pubitemid 34747317)
19. Crowe NY, Coquet JM, Berzins SP, et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 2005; 202:1279-1288
20. Bui JD, Uppaluri R, Hsieh CS, Schreiber RD. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res 2006;66:7301-7309 (Pubitemid 44197712)
21. Betts G, Twohig J, Van den Broek M, Sierro S, Godkin A, Gallimore A. The impact of regulatory T cells on carcinogen-induced sarcogenesis. Br J Cancer 2007;96:1849-1854 (Pubitemid 46912032)
22. Nishikawa H, Kato T, Tawara I, et al. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci U S A 2005;102:9253-9257 (Pubitemid 40923550)
23. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4RSTAT6 pathway. Nat Immunol 2000;1:515-520
24. Seki N, Hayakawa Y, Brooks AD, et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res 2003;63:207-213 (Pubitemid 36070441)
25. Mempel TR, Pittet MJ, Khazaie K, et al. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 2006;25:129-141 (Pubitemid 44066829)
26. Rudge G, Barrett SP, Scott B, van Driel IR. Infiltration of a mesothelioma by IFN-y-producing cells and tumor rejection after depletion of regulatory T cells. J Immunol 2007;178:4089-4096 (Pubitemid 46492357)
27. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-146
28. Pericle F, Giovarelli M, Colombo MP, et al. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 1994;153:5659-5673 (Pubitemid 24377702)
29. Shen Y, Fujimoto S. A tumor-specific Th2 clone initiating tumor rejection via primed CD8+ cytotoxic T-lymphocyte activation in mice. Cancer Res 1996;56:5005-5011 (Pubitemid 26374442)
30. Rodolfo M, Zilocchi C, Accomero P, Cappetti B, Arioli I, Colombo MP. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CDS T lymphocytes that cure lung metastases upon adoptive transfer. J Immunol 1999;163:1923-1928 (Pubitemid 29382193)
31. Dobrzanski MJ, Reome JB, Dutton RW. Therapeutic effects of tumorreactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J Immunol 1999;162:6671-6680
32. Yamaguchi N, Hiraoka S, Mukai T, et al. Induction of tumor regression by administration of B7-lg fusion proteins: mediation by type 2 CD8+ T cells and dependence on IL-4 production. J Immunol 2004; 172:1347-1354 (Pubitemid 38116775)
33. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-716
34. Schuler T, Gin Z, lbe S, Noben-Trauth N, Blankenstein T. T helper cell type 1 -associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med 1999; 189:803-810 (Pubitemid 29189685)
35. Hillman GG, Younes E, Visscher D, et al. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon y: mechanism of action and potential for combination with interleukin 4. Clin Cancer Res 1997;3:1799-1806 (Pubitemid 27444720)
36. Granville CA, Memmott RM, Balogh A, et al. A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. PLoS ONE 2009;4:e5061.
37. Ambrosino E, Spadaro M, lezzi M, et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006;66:7734-7740